Clinical study of oxaliplatin plus raltitrexed versus oxaliplatin plus fluorouracil as first-line treatment for advanced gastric cancer

Abstract

Abstract: AIM: Department of Medical Oncology,Yijishan Hospital,Wannan Medical colleg, Wuhu 241001,Anhui ,ChinaMETHODS: A total of 43 patients with advanced gastric cancer were divided into two groups, 21 cases in Group A:raltitrexed 3 mg/m² ivgtt;d1;oxaliplatin 130 mg/m² ivgtt,d1. 22 cases in Group B:leucovorin 200 mg/m² ivgtt,d1-d5; fluorouracil 375 mg /m² ivgtt,d1-d5; oxaliplatin 130 mg/m² ivgtt,d1. The two regimens were 21days as a cycle,and a total of six cycles was applied unless there was an evidence of disease progression or intolerance of treatment.The efficacy was evaluated after 3-cycle chemotherapy.RESULTS: In Group A and Group B,RR were 47.6% and 31.8% respectively(P=0.289),PFS were 9.8 and 6.6 months respectively(P=0.047). There were differences with the side-effects between the two groups on nausea,sickness and hand-foot syndrome(P＜0.05).Other toxicities were similar.CONCLUSION: Compared with the treatment of oxaliplatin plus fluorouracil,oxaliplatin plus raltitrexed as first-line treatment for advanced gastric cancer has a longer PFS,and the toxicity is well tolerated.

Key words: raltitrexed, 5-flurouracil, oxaliplation, gastric cancer

CLC Number:

HE Yang, PENG Yu-zhen, JI Zhao-ning. Clinical study of oxaliplatin plus raltitrexed versus oxaliplatin plus fluorouracil as first-line treatment for advanced gastric cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 194-198.

References

[1] Shahrokni A,Rajebi M R,Saif M W. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: a challenge or a dilemma[J]?Clin Colorectal Cancer,2009,8 ( 4) : 231-234.
[2] Popov I,Garrato A, Sobrero A,et al.Raltitrexed ( tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomized phaseⅢ Pan-European Trial in Adjuvant Colon Cancer 01 ( PETACC-1 )[J].Eur J Cancer,2008,44( 15) : 2204-2211.
[3] 庄志祥,沈旭东,沈丽琴,等. 雷替曲塞与5 氟尿嘧啶联合奥沙利铂治疗晚期结直肠癌的疗效比较[J]. 苏州大学学报( 医学版), 2010,30(3):573-576,607.
[4] 余嘉文. 雷替曲塞单药二线治疗晚期大肠癌疗效观察[J]. 中国现代药物应用,2012,6(4):18-19.
[5] Waldman BC,Wang Y,Kilaru K,et al.Induction of intrachromosomal homologous recombination in human cells by raltitrexed,an inhibitor of thymidylate synthase[J].DNA Repair(Amst) ,2008,7(10):1624-1635.　
[6] Valentini V, Coco C, Minsky BD, et al. Randomized,multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed ＋ oxaliplatin ＋radiotherapy versus cisplatin ＋ 5-fluorouracil ＋ radiotherapy[J].Int J Radiat Oncol Biol Phys, 2008, 70(2): 403-412.
[7] 崔学尧. 奥沙利铂联合化疗治疗晚期结直肠癌患者56 例疗效分析[J]. 海南医学, 2010,21(12): 62-63.
[8] Maughan T,James R,Kerr D,et al.Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5-FU regimen in the palliative chemotherapy of advanced colorectal cancer ( CRC) : final results of MRC CRO6[J].Ann Oncol,2000,11( Suppl 4) : a1850.
[9] 王佳蕾,李进,秦叔逵,等.雷替曲塞或氟尿嘧啶/亚叶酸钙联合奥沙利铂治疗局部晚期或复发转移性结直肠癌的随机对照多中心Ⅲ期临床试验[J].临床肿瘤学杂志,2012,17(1):6-11.
[10]李瑞中,刘汉锋.进展期胃癌的化学药物治疗现状[J].肿瘤学杂志, 2006,12(6): 504-507.
[11]Kim G P,Sargent D J,Mahoney M R,et al.Phase III noninferiority trial comparing irinotecan with oxaliplatin,fluorouracil,and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841[J].J Clin Oncol,2009,27( 17) : 2848-2854.
[12]Kang HJ,Chang HM,Kim TW,et al.A phase II study of paclitaxel and capecitabine as first-line combination chemotherapy for advanced gastric cancer[J].Br J Cancer,2008,98(2):316-322.
[13]许进军,甘宁. L-OHP联合三种氟尿嘧啶制剂治疗进展期胃癌180例[J].世界华人消化杂志,2014,22( 6) : 853-857.
[14]朱丽晶,沈洁,刘宝瑞等.胃癌中胸苷酸合成酶与培美曲塞/雷替曲塞敏感性的初步研究[J].临床肿瘤学杂志,2012,17(4):301-305.
[15]于丽萍,李斌.多西他赛联合雷替曲塞治疗晚期胃癌的疗效观察[J].中国药房,2012,23(32):3009-3011.
[16]霍丹,张小丽,马玉芳,等. 雷替曲塞联合多西他赛治疗晚期胃癌的临床研究[J].中国现代医药杂志,2011,13(10):27-29.